BPG is committed to discovery and dissemination of knowledge
Featured Articles
7/23/2019 6:56:02 AM | Browse: 58 | Download: 47
Publication Name World Journal of Gastroenterology
Manuscript ID 48028
Country of Manuscript Source Germany
Received
2019-04-06 07:51
Peer-Review Started
2019-04-08 01:16
To Make the First Decision
2019-04-17 00:48
Return for Revision
2019-04-17 02:33
Revised
2019-05-02 06:53
Second Decision
2019-05-17 09:11
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-05-18 12:40
Articles in Press
2019-05-18 12:40
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-07-04 07:10
Publish the Manuscript Online
2019-07-06 06:23
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript type Review
Article Title Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
Manuscript Source Invited Manuscript
All Author List Daniel Neureiter, Sebastian Stintzing, Tobias Kiesslich and Matthias Ocker
Funding Agency and Grant Number
Correspondence To Matthias Ocker, MD, Professor, Translational Medicine Oncology, Bayer AG, Muellerstrasse 178, Berlin 13353, Germany. Matthias.Ocker@bayer.com
Keywords Liver cancer; Immunotherapy; Checkpoint inhibitors; Targeted therapy; Mouse model; Biomarker; Next-generation sequencing; Non-alcoholic steatohepatitis; Fibrosis; Clinical trial
Core Tip Treatment of advanced hepatocellular carcinoma still represents an unmet medical need. Novel therapeutic options comprise new tyrosine kinase inhibitors, epigenetic modifiers and increasingly also cell therapy and immune checkpoint inhibitors and combinations of those modalities. Development of better drugs is closely linked to improved preclinical and animal models and has to be accompanied by the implementation of predictive biomarkers, which is still lacking for hepatocellular carcinoma. The current status of these aspects is reviewed in this manuscript.
Publish Date 2019-07-06 06:23
Citation Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150
Url https://www.wjgnet.com/1007-9327/full/v25/i25/3136.htm
DOI https://dx.doi.org/10.3748/wjg.v25.i25.3136
Full Article (PDF) WJG-25-3136.pdf
Full Article (Word) WJG-25-3136.docx
Manuscript File 48028-Review.docx
Answering Reviewers 48028-Answering reviewers.pdf
Audio Core Tip 48028-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 48028-Conflict-of-interest statement.pdf
Copyright License Agreement 48028-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 48028-Language certificate.pdf
Peer-review Report 48028-Peer-review(s).pdf
Scientific Misconduct Check 48028-Google-MA RY-1.png
Scientific Misconduct Check 48028-Google-MA RY-2.png
Scientific Misconduct Check 48028-Scientific misconduct check.pdf
Scientific Editor Work List 48028-Scientific editor work list.pdf